株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

緑内障手術装置:パイプライン分析

Glaucoma Surgery Devices - Medical Devices Pipeline Assessment, 2017

発行 GlobalData 商品コード 345366
出版日 ページ情報 英文 192 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.00円で換算しております。
Back to Top
緑内障手術装置:パイプライン分析 Glaucoma Surgery Devices - Medical Devices Pipeline Assessment, 2017
出版日: 2017年08月01日 ページ情報: 英文 192 Pages
概要

当レポートでは、世界各国の企業・医療機関などで開発が進められている緑内障手術装置のパイプライン製品情報について分析しており、治験と製品開発の進行状況、段階別・セグメント別・国 (地域) 別の動向、企業と製品の詳細情報、最近の製品開発および業界の動向などの情報を盛り込んでいます。

第1章 目次

第2章 イントロダクション

  • 緑内障手術装置の概要

第3章 開発中の製品

  • 緑内障手術装置 - 開発段階別のパイプライン製品
  • 緑内障手術装置 - セグメント別のパイプライン製品
  • 緑内障手術装置 - 国 (地域) 別のパイプライン製品
  • 緑内障手術装置 - 規制別のパイプライン製品
  • 緑内障手術装置 - 認証時期別 (推定) のパイプライン製品
  • 緑内障手術装置 - 現在進行中の治験

第4章 緑内障手術装置 - 開発中のパイプライン製品:企業別

  • 緑内障手術装置企業 - 開発段階別のパイプライン製品
  • 緑内障手術装置 - 開発段階別のパイプライン製品

第5章 緑内障手術装置企業と製品の概要

  • Anteis S.A.
  • AqueSys, Inc.
  • Assenti, LLC
  • Camras Vision
  • Eye Sonix
  • Galaxy Ophthalmics Inc
  • Geuder AG
  • Glaukos Corporation
  • InnFocus LLC
  • Iowa State University
  • IPI Singapore
  • iScience Interventional, Inc.
  • iSTAR Medical
  • Ivantis, Inc.
  • Konan Medical Inc.
  • Kytogenics Pharmaceuticals, Inc.
  • Massachusetts Eye and Ear Infirmary
  • Medtronic plc
  • Meir Medical Center
  • Ocular Therapeutix, Inc.
  • Oculox Technology Sagl
  • Ocumatrx
  • OcuTherix, Inc.
  • OPKO Health, Inc.
  • OptoLight Vision Technology
  • PolyActiva Pty Ltd
  • Queen's University
  • Refocus Group, Inc.
  • SOLX, Inc.
  • Tel Aviv University
  • TonoGuard Ltd.
  • Transcend Medical, Inc.
  • University of Rostock
  • ViSci Ltd.
  • Westhouse Medical Services Plc

第6章 緑内障手術装置 - 最近の動向

第7章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0398EPD

GlobalData's Medical Devices sector report, "Glaucoma Surgery Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Glaucoma Surgery Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Glaucoma Surgery Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Glaucoma Surgery Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Glaucoma Surgery Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Glaucoma Surgery Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 10

2 Introduction 11

  • 2.1 Glaucoma Surgery Devices Overview 11

3 Products under Development 12

  • 3.1 Glaucoma Surgery Devices - Pipeline Products by Stage of Development 12
  • 3.2 Glaucoma Surgery Devices - Pipeline Products by Segment 13
  • 3.3 Glaucoma Surgery Devices - Pipeline Products by Territory 14
  • 3.4 Glaucoma Surgery Devices - Pipeline Products by Regulatory Path 15
  • 3.5 Glaucoma Surgery Devices - Pipeline Products by Estimated Approval Date 16
  • 3.6 Glaucoma Surgery Devices - Ongoing Clinical Trials 17

4 Glaucoma Surgery Devices - Pipeline Products under Development by Companies 18

  • 4.1 Glaucoma Surgery Devices Companies - Pipeline Products by Stage of Development 18
  • 4.2 Glaucoma Surgery Devices - Pipeline Products by Stage of Development 20

5 Glaucoma Surgery Devices Companies and Product Overview 22

  • 5.1 Anteis SA Company Overview 22
    • 5.1.1 Anteis SA Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.2 Assenti, LLC Company Overview 23
    • 5.2.1 Assenti, LLC Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.3 Camras Vision Company Overview 24
    • 5.3.1 Camras Vision Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.4 Ellex Medical Lasers Limited Company Overview 25
    • 5.4.1 Ellex Medical Lasers Limited Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.5 Eye Sonix Company Overview 26
    • 5.5.1 Eye Sonix Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.6 Galaxy Ophthalmics Inc Company Overview 27
    • 5.6.1 Galaxy Ophthalmics Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.7 Geuder AG Company Overview 28
    • 5.7.1 Geuder AG Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.8 Glaukos Corp Company Overview 29
    • 5.8.1 Glaukos Corp Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.9 iSTAR Medical SA Company Overview 37
    • 5.9.1 iSTAR Medical SA Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.10 Ivantis Inc Company Overview 41
    • 5.10.1 Ivantis Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.11 iVeena Delivery Systems Inc Company Overview 45
    • 5.11.1 iVeena Delivery Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.12 Kytogenics Pharmaceuticals Inc Company Overview 46
    • 5.12.1 Kytogenics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.13 Massachusetts Eye and Ear Infirmary Company Overview 47
    • 5.13.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.14 Medtronic plc Company Overview 48
    • 5.14.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.15 Meir Medical Center Company Overview 49
    • 5.15.1 Meir Medical Center Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.16 MicroOptx, Inc. Company Overview 50
    • 5.16.1 MicroOptx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.17 Oculox Technology Sagl Company Overview 51
    • 5.17.1 Oculox Technology Sagl Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.18 Ocumatrx Company Overview 52
    • 5.18.1 Ocumatrx Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.19 OcuTherix Inc Company Overview 53
    • 5.19.1 OcuTherix Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.20 OPKO Health Inc Company Overview 54
    • 5.20.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.21 OptoLight Vision Technology Company Overview 55
    • 5.21.1 OptoLight Vision Technology Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.22 PolyActiva Pty Ltd Company Overview 56
    • 5.22.1 PolyActiva Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.23 Queen's University Company Overview 57
    • 5.23.1 Queen's University Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.24 Santen Pharmaceutical Co Ltd Company Overview 58
    • 5.24.1 Santen Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.25 Sheba Medical Center Company Overview 61
    • 5.25.1 Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.26 Sight Sciences, Inc. Company Overview 62
    • 5.26.1 Sight Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62
  • 5.27 SOLX Inc Company Overview 65
    • 5.27.1 SOLX Inc Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.28 Tel Aviv University Company Overview 66
    • 5.28.1 Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.29 TonoGuard Ltd. Company Overview 68
    • 5.29.1 TonoGuard Ltd. Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.30 University of Colorado Company Overview 69
    • 5.30.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.31 University of Michigan Company Overview 71
    • 5.31.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 71
  • 5.32 University of Rostock Company Overview 72
    • 5.32.1 University of Rostock Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.33 ViSci Ltd Company Overview 73
    • 5.33.1 ViSci Ltd Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.34 Westhouse Medical Services Plc Company Overview 74
    • 5.34.1 Westhouse Medical Services Plc Pipeline Products & Ongoing Clinical Trials Overview 74

6 Glaucoma Surgery Devices- Recent Developments 75

  • 6.1 Jul 24, 2017: BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert 75
  • 6.2 Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 76
  • 6.3 Jul 06, 2017: Ellex Medical Lasers: Trading Update for the Year Ended 30 June 2017 76
  • 6.4 Jun 26, 2017: Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 78
  • 6.5 Jun 22, 2017: Ocular Therapeutix Announces Executive Transition Plans 78
  • 6.6 Jun 22, 2017: Ellex iTrack Sales and Marketing Activities 79
  • 6.7 Jun 21, 2017: Combining Implantation of Glaukos iStent inject Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study 80
  • 6.8 Jun 21, 2017: Combining Implantation of Glaukos iStent inject Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study 82
  • 6.9 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 83
  • 6.10 May 22, 2017: Study Reveals Potential Cost Efficiency of Using Two Glaukos iStent Trabecular Micro-Bypass Stents to Treat Elevated IOP in Glaucoma Patients 86
  • 6.11 May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results 87
  • 6.12 May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion 88
  • 6.13 May 05, 2017: Ellex iTrack MIGS Technology to Feature at 2017 American Society of Cataract and Refractive Surgery 93
  • 6.14 May 05, 2017: Ocular Therapeutix Reports First Quarter 2017 Financial Results 95
  • 6.15 May 03, 2017: Glaukos Announces First Quarter 2017 Financial Results 97
  • 6.16 May 03, 2017: STAAR Surgical Reports First Quarter 2017 Results 98
  • 6.17 May 02, 2017: Several Surgeon Presentations to Include Glaukos Technologies at 2017 American Society of Cataract and Refractive Surgery 99
  • 6.18 May 01, 2017: Several Surgeon Presentations to Include Glaukos Technologies at 2017 American Society of Cataract and Refractive Surgery 101
  • 6.19 Apr 26, 2017: Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma 104
  • 6.20 Apr 25, 2017: Ivantis Announces FDA Clearance to Initiate Clinical Trial of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery (MIGS) in Patients with Advanced Glaucoma 105
  • 6.21 Apr 19, 2017: Jeffrey Peterson, M.D. first in Hawaii to use new glaucoma surgery device 106
  • 6.22 Apr 13, 2017: International Study Shows Two Glaukos iStent Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP Reduction 107
  • 6.23 Apr 13, 2017: Sight Sciences Announces Health Canada Approval of the VISCO 360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery 108
  • 6.24 Apr 10, 2017: Allergan Receives 2017 ENERGY STAR Partner of the Year - Sustained Excellence Award from U.S. Environmental Protection Agency 109
  • 6.25 Apr 06, 2017: Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy 110
  • 6.26 Apr 06, 2017: Ocular Therapeutix Appoints George Migausky as Interim Chief Financial Officer 110
  • 6.27 Apr 05, 2017: STAAR Surgical Names Deborah Andrews Interim CFO 111
  • 6.28 Mar 22, 2017: Vance Thompson Vision first to use CyPass Micro-Stent in the area 111
  • 6.29 Mar 16, 2017: Glaukos Announces Five-Year Extensions For Three Category III CPT Codes Related To Micro-Invasive Glaucoma Surgery 112
  • 6.30 Mar 14, 2017: USC Roski Eye Institute ophthalmologists are first to use XEN gel stent to treat glaucoma patients in Los Angeles 113
  • 6.31 Mar 10, 2017: Ocular Therapeutix Reports Fourth Quarter and Full Year 2016 Financial Results 114
  • 6.32 Mar 03, 2017: OPKO Health Appoints Dr. Akhtar Ashfaq as Renal Division Senior Vice President, Clinical Research and Development 116
  • 6.33 Mar 02, 2017: STAAR Surgical Reports Fourth Quarter 2016 Results 117
  • 6.34 Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results 118
  • 6.35 Mar 01, 2017: Glaukos Announces Fourth Quarter & Full Year 2016 Financial Results 119
  • 6.36 Feb 28, 2017: Glaukos Technologies Featured in Eight Presentations at 2017 American Glaucoma Society Meeting 121
  • 6.37 Feb 28, 2017: IRIDEX Launches New FDA-Cleared Probe At The Annual American Glaucoma Society Meeting 122
  • 6.38 Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 123
  • 6.39 Feb 27, 2017: Ellex Medical Lasers: Financial Report for Half-Year Ended 31 December 2016 123
  • 6.40 Feb 22, 2017: Preeminent Ophthalmologist, L. Jay Katz Joins Glaukos as Chief Medical Officer 124
  • 6.41 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 125
  • 6.42 Feb 16, 2017: Glaukos Completes Patient Enrollment in Pivotal Phase of U.S. IDE Clinical Trial for iStent SUPRA 128
  • 6.43 Feb 15, 2017: Sight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts 129
  • 6.44 Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016 130
  • 6.45 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 135
  • 6.46 Feb 06, 2017: Joseph Gilliam to Join Glaukos Corporation as Chief Financial Officer and Senior Vice President of Corporate Development 136
  • 6.47 Feb 02, 2017: Ellex Trading Update for the Six Months Ended 31 December 2016 136
  • 6.48 Feb 01, 2017: Glaukos Promotes Chris M. Calcaterra to Chief Operating Officer 138
  • 6.49 Jan 05, 2017: Allergan to Present at Goldman Sachs Healthcare CEOs Unscripted Conference and Provides Preliminary Comments on 2017 Outlook 139

7 Appendix 189

  • 7.1 Methodology 189
  • 7.2 About GlobalData 192
  • 7.3 Contact Us 192
  • 7.4 Disclaimer 192

List of Tables

1.1 List of Tables

  • Table 1: Glaucoma Surgery Devices - Pipeline Products by Stage of Development 12
  • Table 2: Glaucoma Surgery Devices - Pipeline Products by Segment 13
  • Table 3: Glaucoma Surgery Devices - Pipeline Products by Territory 14
  • Table 4: Glaucoma Surgery Devices - Pipeline Products by Regulatory Path 15
  • Table 5: Glaucoma Surgery Devices - Pipeline Products by Estimated Approval Date 16
  • Table 6: Glaucoma Surgery Devices - Ongoing Clinical Trials 17
  • Table 7: Glaucoma Surgery Devices Companies - Pipeline Products by Stage of Development 18
  • Table 8: Glaucoma Surgery Devices - Pipeline Products by Stage of Development 20
  • Table 9: Anteis SA Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 10: Drainage Viscoelastic Injectable Implant - Product Status 22
  • Table 11: Drainage Viscoelastic Injectable Implant - Product Description 22
  • Table 12: Assenti, LLC Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 13: Intraocular Pressure Monitoring System - Product Status 23
  • Table 14: Intraocular Pressure Monitoring System - Product Description 23
  • Table 15: Camras Vision Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 16: Camras Shunt - Product Status 24
  • Table 17: Camras Shunt - Product Description 24
  • Table 18: Ellex Medical Lasers Limited Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 19: Glaucoma Device - Product Status 25
  • Table 20: Glaucoma Device - Product Description 25
  • Table 21: Eye Sonix Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 22: Therapeutic Ultrasound Device - Glaucoma - Product Status 26
  • Table 23: Therapeutic Ultrasound Device - Glaucoma - Product Description 26
  • Table 24: Galaxy Ophthalmics Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 25: Titan Shunt - Product Status 27
  • Table 26: Titan Shunt - Product Description 27
  • Table 27: Geuder AG Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 28: MikroAug - Product Status 28
  • Table 29: MikroAug - Product Description 28
  • Table 30: Glaukos Corp Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 31: GTS400 - Product Status 29
  • Table 32: GTS400 - Product Description 29
  • Table 33: iStent Inject - Cataract Surgery - Product Status 30
  • Table 34: iStent Inject - Cataract Surgery - Product Description 30
  • Table 35: iStent Inject - Standalone Procedures - Product Status 30
  • Table 36: iStent Inject - Standalone Procedures - Product Description 31
  • Table 37: iStent Supra Suprachoroidal Micro-Bypass Stent - Product Status 31
  • Table 38: iStent Supra Suprachoroidal Micro-Bypass Stent - Product Description 31
  • Table 39: Glaukos Corp - Ongoing Clinical Trials Overview 32
  • Table 40: iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 33
  • Table 41: iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated with One Suprachoroidal Stent 33
  • Table 42: iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin 33
  • Table 43: iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction with Cataract Surgery 34
  • Table 44: iStent Inject - Cataract Surgery - A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naive to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% 35
  • Table 45: iStent Inject - Cataract Surgery - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction with Cataract Surgery 35
  • Table 46: iStent Inject - Cataract Surgery - A Randomized Controlled Trial of Cataract Surgery Versus Combined Cataract Surgery with Insertion of iStent Inject 35
  • Table 47: iStent Inject - Standalone Procedures - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 36
  • Table 48: iStent Inject - Standalone Procedures - Initial Phase of U.S. IDE Clinical Trial for Standalone Version of iStent inject 36
  • Table 49: iStent Inject - Standalone Procedures - The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients With Glaucoma or Ocular Hypertension: An Observational Study 36
  • Table 50: iSTAR Medical SA Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 51: MINIject - Product Status 37
  • Table 52: MINIject - Product Description 37
  • Table 53: STARflo MINI - Product Status 38
  • Table 54: STARflo MINI - Product Description 38
  • Table 55: STARflo Plus Glaucoma Implant - Product Status 38
  • Table 56: STARflo Plus Glaucoma Implant - Product Description 38
  • Table 57: iSTAR Medical SA - Ongoing Clinical Trials Overview 39
  • Table 58: MINIject - A Prospective, Open, Multicenter Clinical Trial with One Cohort Analysing the Efficacy and Safety of MINIject in Patients with Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications 40
  • Table 59: Ivantis Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 60: Hydrus Microstent - Product Status 41
  • Table 61: Hydrus Microstent - Product Description 41
  • Table 62: Ivantis Inc - Ongoing Clinical Trials Overview 42
  • Table 63: Hydrus Microstent - A Prospective, Multicenter, Randomized Comparison of the Hydrus Microstent to the iStent for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery 43
  • Table 64: Hydrus Microstent - Evaluation of Safety and Efficacy of the Hydrus Microstent in Treatment of Patients with Advanced Glaucoma 43
  • Table 65: Hydrus Microstent - The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients With Glaucoma or Ocular Hypertension: An Observational Study 43
  • Table 66: Hydrus Microstent - The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial 43
  • Table 67: iVeena Delivery Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 68: IVMED-70 - Product Status 45
  • Table 69: IVMED-70 - Product Description 45
  • Table 70: Kytogenics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 71: MACC-Based Device - Glaucoma Filtering - Product Status 46
  • Table 72: MACC-Based Device - Glaucoma Filtering - Product Description 46
  • Table 73: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 74: Pressure Relief Valve Shunt - Product Status 47
  • Table 75: Pressure Relief Valve Shunt - Product Description 47
  • Table 76: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 77: CellPlant - Product Status 48
  • Table 78: CellPlant - Product Description 48
  • Table 79: Meir Medical Center Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 80: Glaucoma Drainage Device - Product Status 49
  • Table 81: Glaucoma Drainage Device - Product Description 49
  • Table 82: MicroOptx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 83: Brown Glaucoma Implant (BGI) - Product Status 50
  • Table 84: Brown Glaucoma Implant (BGI) - Product Description 50
  • Table 85: Oculox Technology Sagl Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 86: Intraocular Piezoresistive Pressure Sensor - Product Status 51
  • Table 87: Intraocular Piezoresistive Pressure Sensor - Product Description 51
  • Table 88: Ocumatrx Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 89: CaPRI Device - Product Status 52
  • Table 90: CaPRI Device - Product Description 52
  • Table 91: OcuTherix Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 92: Deep Wave Trabeculoplasty Device - Product Status 53
  • Table 93: Deep Wave Trabeculoplasty Device - Product Description 53
  • Table 94: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 95: Aquashunt - Product Status 54
  • Table 96: Aquashunt - Product Description 54
  • Table 97: OptoLight Vision Technology Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 98: Lipshitz Macular Implant For Advanced Glaucoma - Product Status 55
  • Table 99: Lipshitz Macular Implant For Advanced Glaucoma - Product Description 55
  • Table 100: PolyActiva Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 101: Fully Bioerodible Ocular Implant - Glaucoma - Product Status 56
  • Table 102: Fully Bioerodible Ocular Implant - Glaucoma - Product Description 56
  • Table 103: Queen's University Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 104: Laser Adjustable Suture - Product Status 57
  • Table 105: Laser Adjustable Suture - Product Description 57
  • Table 106: Santen Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 107: InnFocus Microshunt - Product Status 58
  • Table 108: InnFocus Microshunt - Product Description 58
  • Table 109: Santen Pharmaceutical Co Ltd - Ongoing Clinical Trials Overview 59
  • Table 110: InnFocus Microshunt - A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShunt Glaucoma Drainage System to Standard Trabeculectomy In Subjects with Primary Open Angle Glaucoma 60
  • Table 111: InnFocus Microshunt - Post Market Study to Evaluate Safety and Effectiveness of the InnFocus Microshunt (MIDI Arrow) in Patients with Primary Open Angle Glaucoma 60
  • Table 112: Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 113: Toroidal Glaucoma Drainage Device - Product Status 61
  • Table 114: Toroidal Glaucoma Drainage Device - Product Description 61
  • Table 115: Sight Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 116: VISCO 360 Viscosurgical System - Primary Open Angle Glaucoma - Product Status 62
  • Table 117: VISCO 360 Viscosurgical System - Primary Open Angle Glaucoma - Product Description 62
  • Table 118: Sight Sciences, Inc. - Ongoing Clinical Trials Overview 63
  • Table 119: VISCO 360 Viscosurgical System - Primary Open Angle Glaucoma - Multi-center, Prospective, Randomized, Controlled Clinical Evaluation of the Safety and Effectiveness of the Sight Sciences VISCO360 Viscosurgical System in Canaloplasty Versus Selective Laser Trabeculoplasty in the Reduction of IOP in Primary Open Angle Glaucoma 64
  • Table 120: SOLX Inc Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 121: SOLX Gold Shunt - Product Status 65
  • Table 122: SOLX Gold Shunt - Product Description 65
  • Table 123: Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 124: Direct Laser Trabeculoplasty System - Product Status 66
  • Table 125: Direct Laser Trabeculoplasty System - Product Description 66
  • Table 126: Glaucoma Implant - Product Status 67
  • Table 127: Glaucoma Implant - Product Description 67
  • Table 128: TonoGuard Ltd. Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 129: EasyIOP - Product Status 68
  • Table 130: EasyIOP - Product Description 68
  • Table 131: University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 132: Aqueous Humor Micro-Bypass Shunt - Product Status 69
  • Table 133: Aqueous Humor Micro-Bypass Shunt - Product Description 69
  • Table 134: Glaucoma Device - Product Status 70
  • Table 135: Glaucoma Device - Product Description 70
  • Table 136: University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 137: Magnetoelastic Actuator - Product Status 71
  • Table 138: Magnetoelastic Actuator - Product Description 71
  • Table 139: University of Rostock Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 140: PTX-Eluting Microstent - Product Status 72
  • Table 141: PTX-Eluting Microstent - Product Description 72
  • Table 142: ViSci Ltd Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 143: Eye-D - Product Status 73
  • Table 144: Eye-D - Product Description 73
  • Table 145: Westhouse Medical Services Plc Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 146: Pneumatic Trabeculoplasty System - Product Status 74
  • Table 147: Pneumatic Trabeculoplasty System - Product Description 74
  • Table 148: Glossary 191

List of Figures

1.2 List of Figures

  • Figure 1: Glaucoma Surgery Devices - Pipeline Products by Stage of Development 12
  • Figure 2: Glaucoma Surgery Devices - Pipeline Products by Segment 13
  • Figure 3: Glaucoma Surgery Devices - Pipeline Products by Territory 14
  • Figure 4: Glaucoma Surgery Devices - Pipeline Products by Regulatory Path 15
  • Figure 5: Glaucoma Surgery Devices - Pipeline Products by Estimated Approval Date 16
  • Figure 6: Glaucoma Surgery Devices - Ongoing Clinical Trials 17
Back to Top